Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma director Clarke Trafford received a new stock option grant as part of his compensation. He was awarded options for 33,435 shares of common stock at an exercise price of
Traws Pharma, Inc. director Werner Cautreels received a grant of stock options as compensation. He was awarded 31,258 options to buy common stock at an exercise price of
Traws Pharma director John Harold Leaman received a stock option grant for 33,435 shares of common stock. The options have an exercise price of $1.60 per share and were awarded at no upfront cost as compensation. According to the award terms, the options will vest 100% on the first anniversary of the March 8, 2026 grant date, after which they become exercisable. Following this grant, Leaman holds 33,435 stock options directly.
Traws Pharma, Inc. granted Chief Executive Officer Iain D. Dukes stock options covering 231,336 shares of common stock. The options have a
Traws Pharma, Inc. reported that Chief Science Officer Virology Charles David Pauza received a grant of 118,367 stock options to buy common stock at an exercise price of
Traws Pharma, Inc. reported that its Chief Operating Officer, Nikolay Savchuk, received a grant of stock options as part of his compensation. He was awarded 96,899 stock options to buy common shares at an exercise price of $1.60 per share, expiring on March 8, 2036. These options were granted under the company’s 2021 Incentive Compensation Plan and will vest 100% on the first anniversary of the grant date, meaning they become fully exercisable after one year. Following this grant, he holds 96,899 options, and there were no open‑market purchases or sales reported in this filing.
Traws Pharma, Inc. reported that director Jack E. Stover received a grant of stock options covering 33,435 shares of common stock. The options have an exercise price of
Traws Pharma, Inc. reported that Chief Medical Officer Robert Redfield received a grant of stock options covering 108,854 shares of common stock. These options have an exercise price of
The options will vest 100% on the first anniversary of the
Traw Pharma, Inc. director Mary Teresa Shoemaker reported a grant of stock options as equity compensation. She received options covering 33,435 shares of common stock with an exercise price of $1.6000 per share, awarded by the company’s compensation committee under its 2021 Incentive Compensation Plan.
The options will vest 100% on the first anniversary of the 2026-03-08 grant date and expire on 2036-03-08. Following this award, Shoemaker holds 33,435 stock options directly.
Traws Pharma, Inc. filed an 8-K after completing analysis of a 90-patient, open-label Phase 2 study of oral ratutrelvir versus PAXLOVID® in mild-to-moderate COVID-19, including a PAXLOVID®-ineligible arm. PAXLOVID®-ineligible patients on ratutrelvir reported fewer treatment-related adverse events (10% vs 23.3%) and faster symptom resolution (HR 1.31; 95% CI 0.78–2.20; p=0.018), with no viral rebound observed in ratutrelvir-treated patients.
The company also reported that a tablet formulation of tivoxavir marboxil increased exposure by 30% versus a prototype, with modeling suggesting 28-day influenza protection and plans for a prophylaxis challenge study. Separately, the FDA placed the U.S. IND for tivoxavir marboxil on clinical hold over mutagenicity data, with formal feedback expected by March 16, 2026.